Neil J Scolding

List of Publications by Year
in descending order

132 papers	5,562 citations	70961 41 h-index	85405 71 g-index
134 all docs	134 docs citations	134 times ranked	5900 citing authors

#	Article	IF	Citations
1	Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. JAMA - Journal of the American Medical Association, 2019, 321, 175.	3.8	336
2	AÂ-related angiitis: primary angiitis of the central nervous system associated with cerebral amyloid angiopathy. Brain, 2005, 128, 500-515.	3.7	329
3	Human bone marrow-derived mesenchymal stem cells secrete brain-derived neurotrophic factor which promotes neuronal survival in vitro. Stem Cell Research, 2009, 3, 63-70.	0.3	253
4	Vesicular removal by oligodendrocytes of membrane attack complexes formed by activated complement. Nature, 1989, 339, 620-622.	13.7	237
5	The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group. Multiple Sclerosis Journal, 2010, 16, 503-510.	1.4	212
6	Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. Practical Neurology, 2015, 15, 273-279.	0.5	169
7	Cell-based therapeutic strategies for multiple sclerosis. Brain, 2017, 140, 2776-2796.	3.7	139
8	INTERACTIONS BETWEEN OLIGODENDROCYTES AND MICROGLIA. Brain, 1992, 115, 1611-1631.	3.7	138
9	Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. Lancet Neurology, The, 2017, 16, 271-281.	4.9	134
10	INTERACTIONS BETWEEN OLIGODENDROCYTES AND MICROGLIA. Brain, 1992, 115, 1611-1631.	3.7	126
11	Myelin-oligodendrocyte glycoprotein (MOG) is a surface marker of oligodendrocyte maturation. Journal of Neuroimmunology, 1989, 22, 169-176.	1.1	119
12	Human mesenchymal stem cells abrogate experimental allergic encephalomyelitis after intraperitoneal injection, and with sparse CNS infiltration. Neuroscience Letters, 2008, 448, 71-73.	1.0	116
13	Normal rat serum cytotoxicity against syngeneic oligodendrocytes. Journal of the Neurological Sciences, 1989, 89, 289-300.	0.3	113
14	A proliferative adult human oligodendrocyte progenitor. NeuroReport, 1995, 6, 441-445.	0.6	113
15	Mesenchymal stem cellâ€secreted superoxide dismutase promotes cerebellar neuronal survival. Journal of Neurochemistry, 2010, 114, 1569-1580.	2.1	107
16	Review: Glial lineages and myelination in the central nervous system. Journal of Anatomy, 1997, 190, 161-200.	0.9	96
17	Mechanisms of damage to myelin and oligodendrocytes and their relevance to disease. Neuropathology and Applied Neurobiology, 1999, 25, 435-458.	1.8	96
18	Identification of A2B5-positive putative oligodendrocyte progenitor cells and A2B5-positive astrocytes in adult human white matter. Neuroscience, 1999, 89, 1-4.	1.1	86

#	Article	IF	Citations
19	Human Mesenchymal Stem Cells Infiltrate the Spinal Cord, Reduce Demyelination, and Localize to White Matter Lesions in Experimental Autoimmune Encephalomyelitis. Journal of Neuropathology and Experimental Neurology, 2010, 69, 1087-1095.	0.9	85
20	Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort. Multiple Sclerosis Journal, 2016, 22, 1215-1223.	1.4	85
21	The neuropathology and pathogenesis of systemic lupus erythematosus. Neuropathology and Applied Neurobiology, 2002, 28, 173-189.	1.8	83
22	Neurosarcoidosis: a clinical approach to diagnosis and management. Journal of Neurology, 2017, 264, 1023-1028.	1.8	81
23	Mechanisms of Oxidative Damage in Multiple Sclerosis and a Cell Therapy Approach to Treatment. Autoimmune Diseases, 2011, 2011, 1-11.	2.7	80
24	Safety and Feasibility of Autologous Bone Marrow Cellular Therapy in Relapsing-Progressive Multiple Sclerosis. Clinical Pharmacology and Therapeutics, 2010, 87, 679-685.	2.3	75
25	Adult stem cellsâ€"reprogramming neurological repair?. Lancet, The, 2004, 364, 193-199.	6.3	70
26	Preclinical development and first-in-human study of ATX-MS-1467 for immunotherapy of MS. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e93.	3.1	70
27	Axon loss in multiple sclerosis. Lancet, The, 1998, 352, 340-341.	6.3	68
28	The expression of complement regulatory proteins by adult human oligodendrocytes. Journal of Neuroimmunology, 1998, 84, 69-75.	1.1	62
29	Characterization of in vitro expanded bone marrow-derived mesenchymal stem cells from patients with multiple sclerosis. Multiple Sclerosis Journal, 2010, 16, 909-918.	1.4	62
30	Neurolupus. Practical Neurology, 2010, 10, 4-15.	0.5	59
31	Cerebral vasculitis--recognition, diagnosis and management. QJM - Monthly Journal of the Association of Physicians, 1997, 90, 61-73.	0.2	58
32	Primary progressive multiple sclerosis: progress and challenges. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1100-1106.	0.9	56
33	Cell therapy for multiple sclerosis: an evolving concept with implications for other neurodegenerative diseases. Lancet, The, 2013, 382, 1204-1213.	6.3	54
34	The pathogenesis of demyelinating disease. Progress in Neurobiology, 1994, 43, 143-173.	2.8	53
35	Oligodendrocyte susceptibility to injury by T-cell perforin. Immunology, 1990, 70, 6-10.	2.0	52
36	Human bone marrow mesenchymal stem cells protect catecholaminergic and serotonergic neuronal perikarya and transporter function from oxidative stress by the secretion of glial-derived neurotrophic factor. Brain Research, 2012, 1431, 86-96.	1.1	50

#	Article	IF	Citations
37	Oxidative stress-related biomarkers in multiple sclerosis: a review. Biomarkers in Medicine, 2016, 10, 889-902.	0.6	49
38	Cell transplantation, myelin repair, and multiple sclerosis. Lancet Neurology, The, 2002, 1, 31-40.	4.9	48
39	Oligodendroglia are protected from antibody-mediated complement injury by normal immunoglobulins (â€œIVIgâ€). Journal of Neuroimmunology, 2000, 103, 195-201.	1.1	47
40	The recognition, diagnosis and management of cerebral vasculitis: a European survey. European Journal of Neurology, 2002, 9, 343-347.	1.7	45
41	Central nervous system vasculitis. Seminars in Immunopathology, 2009, 31, 527-536.	2.8	45
42	The diagnosis of primary central nervous system vasculitis. Practical Neurology, 2020, 20, 109-114.	0.5	43
43	Reversible injury of cultured rat oligodendrocytes by complement. Immunology, 1989, 67, 441-6.	2.0	42
44	Cerebral Vasculitis: A Practical Approach. Practical Neurology, 2002, 2, 80-93.	0.5	39
45	Percutaneous Endoscopic Gastrostomy Tube Insertion in Neurodegenerative Disease: A Retrospective Study and Literature Review. Clinical Endoscopy, 2017, 50, 270-278.	0.6	39
46	Glial cells as targets for cytotoxic immune mediators. Glia, 2001, 36, 200-211.	2.5	38
47	Remyelination of Demyelinated CNS Axons by Transplanted Human Schwann Cells: The Deleterious Effect of Contaminating Fibroblasts. Cell Transplantation, 2001, 10, 305-315.	1.2	38
48	Purkinje cell fusion and binucleate heterokaryon formation in multiple sclerosis cerebellum. Brain, 2012, 135, 2962-2972.	3.7	38
49	Assessment of bone marrow-derived Cellular Therapy in progressive Multiple Sclerosis (ACTiMuS): study protocol for a randomised controlled trial. Trials, 2015, 16, 463.	0.7	37
50	Disease-responsive neural precursor cells are present in multiple sclerosis lesions. Regenerative Medicine, 2008, 3, 835-847.	0.8	36
51	Purkinje cell injury, structural plasticity and fusion in patients with Friedreichâ€™s ataxia. Acta Neuropathologica Communications, 2016, 4, 53.	2.4	36
52	Reduced cellularity of bone marrow in multiple sclerosis with decreased MSC expansion potential and premature ageing in vitro. Multiple Sclerosis Journal, 2018, 24, 919-931.	1.4	35
53	The role of calcium in rat oligodendrocyte injury and repair. Neuroscience Letters, 1992, 135, 95-98.	1.0	34
54	Autologous bone marrow stem cells â€” properties and advantages. Journal of the Neurological Sciences, 2008, 265, 59-62.	0.3	32

#	Article	IF	Citations
55	Oligodendrocyte-macrophage interactions in vitro triggered by specific antibodies. Immunology, 1991, 72, 127-32.	2.0	32
56	Overexpression of Kinesin Superfamily Motor Proteins in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 60, 1511-1524.	1.2	29
57	Reduced neuroprotective potential of the mesenchymal stromal cell secretome with ex vivo expansion, age and progressive multiple sclerosis. Cytotherapy, 2018, 20, 21-28.	0.3	27
58	Dysregulation of Mesenchymal Stromal Cell Antioxidant Responses in Progressive Multiple Sclerosis. Stem Cells Translational Medicine, 2018, 7, 748-758.	1.6	27
59	Factors affecting mortality after traumatic brain injury in a resource-poor setting. BJS Open, 2020, 4, 320-325.	0.7	25
60	Mesenchymal Stem Cells Restore Frataxin Expression and Increase Hydrogen Peroxide Scavenging Enzymes in Friedreich Ataxia Fibroblasts. PLoS ONE, 2011, 6, e26098.	1.1	24
61	Autologous mesenchymal bone marrow stem cells: Practical considerations. Journal of the Neurological Sciences, 2008, 265, 111-115.	0.3	23
62	Brain biopsy in cryptogenic neurological disease. British Journal of Neurosurgery, 2011, 25, 614-620.	0.4	23
63	Reductions in kinesin expression are associated with nitric oxideâ€induced axonal damage. Journal of Neuroscience Research, 2015, 93, 882-892.	1.3	23
64	Complement mediated serum cytotoxicity against oligodendrocytes: a comparison with other cells of the oligodendrocyte-type 2 astrocyte lineage. Journal of the Neurological Sciences, 1990, 97, 155-162.	0.3	22
65	Stem cells for the treatment of neurological disease. Transfusion Medicine, 2003, 13, 351-361.	0.5	22
66	Prolonged disorders of consciousness: a critical evaluation of the new UK guidelines. Brain, 2021, 144, 1655-1660.	3.7	22
67	Immune Mechanisms in the Pathogenesis of Demyelinating Diseases. Autoimmunity, 1989, 4, 131-142.	1.2	21
68	New cells from old. Lancet, The, 2001, 357, 329-330.	6.3	19
69	Cell Therapy for Multiple Sclerosis. CNS Drugs, 2017, 31, 453-469.	2.7	19
70	Stem-cell therapy: hope and hype. Lancet, The, 2005, 365, 2073-2075.	6.3	18
71	Increased microglial catalase activity in multiple sclerosis grey matter. Brain Research, 2014, 1559, 55-64.	1.1	18
72	Cerebral amyloid angiopathy related vasculitis: successful treatment with azathioprine. Journal of Neurology, 2010, 257, 2103-2105.	1.8	16

#	Article	IF	Citations
73	Aberrant cerebellar Purkinje cell function repaired in vivo by fusion with infiltrating bone marrow-derived cells. Acta Neuropathologica, 2018, 135, 907-921.	3.9	16
74	Nodding syndrome: a concise review. Brain Communications, 2020, 2, fcaa037.	1.5	16
75	Rare side effects of alemtuzumab remind us of the need for postmarketing surveillance. Neurology, 2018, 90, 819-820.	1.5	15
76	Enhanced green fluorescent protein-expressing human mesenchymal stem cells retain neural marker expression. Journal of Neuroimmunology, 2008, 193, 59-67.	1.1	14
77	Repeat infusion of autologous bone marrow cells in multiple sclerosis: protocol for a phase I extension study (SIAMMS-II). BMJ Open, 2015, 5, e009090.	0.8	14
78	Bone marrow transplantation stimulates neural repair in Friedreich's ataxia mice. Annals of Neurology, 2018, 83, 779-793.	2.8	14
79	Acute disseminated encephalomyelitis and other inflammatory demyelinating variants. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 122, 601-611.	1.0	13
80	Idiopathic hypereosinophilic syndrome: a new cause of vasculitis of the central nervous system. Journal of Neurology, 2015, 262, 1354-1359.	1.8	13
81	Intracranial spread of IgG4-related disease via skull base foramina. Practical Neurology, 2016, 16, 240-242.	0.5	13
82	Human Mesenchymal Stem Cell Culture for Neural Transplantation. Methods in Molecular Biology, 2009, 549, 103-118.	0.4	12
83	Grovith factors fail to protect rat oligodendrocytes against humoral injury in vitro. Neuroscience Letters, 1995, 183, 75-78.	1.0	11
84	Cell therapy in demyelinating diseases. NeuroRx, 2004, 1, 415-423.	6.0	11
85	Devic's disease and autoantibodies. Lancet Neurology, The, 2005, 4, 136-7.	4.9	11
86	Mesenchymal Stem Cells and Neurodegenerative Disease. Clinical Pharmacology and Therapeutics, 2009, 85, 19-20.	2.3	10
87	Remyelination of demyelinated CNS axons by transplanted human schwann cells: the deleterious effect of contaminating fibroblasts. Cell Transplantation, 2001, 10, 305-15.	1.2	10
88	Ovarioleukodystrophy due toEIF2B5mutations. Practical Neurology, 2016, 16, 496-499.	0.5	9
89	Can diffusion-weighted imaging improve the diagnosis of CNS vasculitis?. Nature Clinical Practice Neurology, 2007, 3, 608-609.	2.7	8
90	Multipotent adult progenitor cell isolation and proliferation in cytokine and serumâ€free medium conditioned by rat B104 cells. British Journal of Haematology, 2010, 148, 441-444.	1.2	8

#	Article	IF	Citations
91	Stem cells in genetic myelin disorders. Regenerative Medicine, 2010, 5, 425-439.	0.8	8
92	Mesenchymal Stem Cell-Derived Factors Restore Function to Human Frataxin-Deficient Cells. Cerebellum, 2017, 16, 840-851.	1.4	8
93	Immune reconstitution and treatment response in multiple sclerosis following alemtuzumab. Neurology, 2014, 82, 2150-2151.	1.5	7
94	Advising patients seeking stem cell interventions for multiple sclerosis. Practical Neurology, 2018, 18, 472-476.	0.5	7
95	Tetanus in a rural low-income intensive care unit setting. Brain Communications, 2021, 3, fcab013.	1.5	7
96	Strategies for achieving and monitoring myelin repair. Journal of Neurology, 2007, 254, 275-283.	1.8	5
97	Tumefactive demyelination presenting during bevacizumab treatment. BMJ Case Reports, 2015, 2015, bcr2015212173.	0.2	5
98	Remyelination in demyelinating disease. BailliÃ¨re's Clinical Neurology, 1997, 6, 525-48.	0.2	5
99	CNS involvement in systemic vasculitides. Journal of the Neurological Sciences, 2021, 424, 117423.	0.3	4
100	Response to: â€˜Nodding syndrome, many questions remain but we can prevent it by eliminating onchocerciasisâ€™. Brain Communications, 2021, 3, fcaa229.	1.5	3
101	Erdheim-Chester disease: 25-year history with early CNS involvement. BMJ Case Reports, 2016, 2016, bcr2016216747.	0.2	3
102	OPTIMISE: MS study protocol: a pragmatic, prospective observational study to address the need for, and challenges with, real world pharmacovigilance in multiple sclerosis. BMJ Open, 2021, 11, e050176.	0.8	3
103	Reduced expression of mitochondrial fumarate hydratase in progressive multiple sclerosis contributes to impaired in vitro mesenchymal stromal cell-mediated neuroprotection. Multiple Sclerosis Journal, 2022, 28, 1179-1188.	1.4	3
104	Paraneoplastic sensory neuropathy and Purkinje cell antibodies. Muscle and Nerve, 1999, 22, 1466-1467.	1.0	2
105	Chapter 44 Vasculitis and stroke. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 93, 873-886.	1.0	2
106	The other BSE. Brain, 2011, 134, 2194-2196.	3.7	2
107	Alemtuzumab and Fatal Myocarditis. Neurology: Clinical Practice, 2021, 11, e46-e47.	0.8	2
108	Brain biopsy before or after treatment with corticosteroids?. Neuroradiology, 2020, 62, 545-546.	1.1	2

#	Article	IF	Citations
109	Maternal micro-chimeric cells in the multiple sclerosis brain. Multiple Sclerosis and Related Disorders, 2020, 40, 101925.	0.9	2
110	Review: Glial lineages and myelination in the central nervous system. , 0, .		2
111	The neurology of chronic nodding syndrome. Brain Communications, 2022, 4, .	1.5	2
112	A Young Man with a Fatal Encephalopathy. Practical Neurology, 2002, 2, 26-35.	0.5	1
113	Subacute neurological syndromes. Clinical Medicine, 2004, 4, 122-124.	0.8	1
114	Future Therapies for Progressive Multiple Sclerosis. , 2013, , 221-243.		1
115	Neurology and what?. Brain, 2020, 143, 1613-1615.	3.7	1
116	CENTRAL NERVOUS SYSTEM ANGIITIS.. Brain, 2000, 123, 2364-2365.	3.7	0
117	Use of stem cells in creation of embryos. Lancet, The, 2001, 358, 2078.	6.3	0
118	New Cells, New Brain. Practical Neurology, 2002, 2, 128-129.	0.5	0
119	First attack in multiple sclerosis: harbinger or history?. Lancet Neurology, The, 2003, 2, 526.	4.9	0
120	Cerebral Vasculitis. , 0, , 510-515.		0
121	PAF66 Brain biopsy in neurological disease. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, e17-e17.	0.9	0
122	We are about to cure multiple sclerosis in the next 10 years, even though we do not know its cause: Yes. Multiple Sclerosis Journal, 2012, 18, 782-783.	1.4	0
123	CD34+ STEM CELL MOBILISATION IN MS TREATMENT AND RELAPSE. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, e4.61-e4.	0.9	0
124	PATIENT-REPORTED OUTCOMES AND DISABILITY IN MULTIPLE SCLEROSIS. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, e4.32-e4.	0.9	0
125	The best clinical paper on multiple sclerosis in 2014. Multiple Sclerosis Journal, 2015, 21, 854-855.	1.4	0
126	Can the optic nerve be repaired?. Lancet Neurology, The, 2017, 16, 172-173.	4.9	0

#	Article	IF	Citations
127	Future Therapies for Progressive Multiple Sclerosis. , 2018, , 275-300.		0
128	Stem Cells for Multiple Sclerosis. , 2016, , 259-273.		0
129	Cell therapy in demyelinating diseases. Neurotherapeutics, 2004, 1, 415-423.	2.1	0
130	Neural cell transplantation: methods and protocols. Preface. Methods in Molecular Biology, 2009, 549, v.	0.4	0
131	Amyloid cerebrovasculopathies. Practical Neurology, 2022, , practneurol-2022-003386.	0.5	0
132	Repeat infusion of autologous bone marrow cells in progressive multiple sclerosis â€“ A phase I extension study (SIAMMS II). Multiple Sclerosis and Related Disorders, 2022, 61, 103782.	0.9	0